Xulane: payments to doctors
Payments that named Xulane as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $303K
- Providers
- 6,555
- Transactions
- 15,067
- Average per transaction
- $20
The per-transaction average — $20 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 6,555 providers the average total is $46, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Mylan Pharmaceuticals Inc. | $298,032 | 98.4% |
| Mylan Inc. | $3,857 | 1.3% |
| Mylan Specialty L.p. | $1,055 | 0.3% |